OrthoLogic Appoints Les Taeger Chief Financial Officer
11 Enero 2006 - 7:00AM
PR Newswire (US)
TEMPE, Ariz., Jan. 11 /PRNewswire-FirstCall/ -- OrthoLogic Corp.
(NASDAQ:OLGC) today announced the appointment of Les Taeger to the
position of Senior Vice President and Chief Financial Officer,
effective January 16, 2006. Mr. Taeger joins OrthoLogic from
Cardiotech International, and its predecessor Gish Biomedical,
where he was Chief Financial Officer for the last five years. He
will report directly to James Pusey MD, President and CEO of
OrthoLogic. Mr. Taeger has been a CFO for over 15 years and has
significant experience in mergers and acquisitions, financing, SEC
reporting and compliance, including implementation of the
Sarbanes-Oxley Act provisions. He has been a CPA for more than 22
years and prior to serving as a CFO, he served in roles that
included substantial audit and general financial management
responsibilities. Commenting on Mr. Taeger's appointment, Dr. Pusey
said, "This is a very exciting time for OrthoLogic, and we welcome
Les with his deep, highly-regarded background and 'hands-on'
style." Mr. Taeger will replace Sherry Sturman, who will remain a
consultant to the company. "We wish Ms. Sturman the best in her
future endeavors and thank her for her valuable contributions in
transforming OrthoLogic into a fully integrated biotechnology
company," said Dr. Pusey. About OrthoLogic OrthoLogic is a
biotechnology company focused on the development and
commercialization of the novel synthetic peptide Chrysalin(R)
(TP508) in three lead indications, all of which represent areas of
significant unmet medical need -- fracture repair, diabetic foot
ulcer healing and cartilage defect repair. Based on the Company's
pioneering scientific research of the natural healing cascade,
OrthoLogic has become the leading company focused on tissue and
bone repair. OrthoLogic is committed to developing a pipeline of
novel peptides and other molecules aimed at helping patients with
equally under-served conditions. The Company maintains exclusive
worldwide rights for Chrysalin. OrthoLogic's corporate headquarters
are in Tempe, Arizona. For more information, please visit the
company's Web site: http://www.orthologic.com/. Statements in this
press release or otherwise attributable to OrthoLogic regarding our
business that are not historical facts are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements, which include the
timing and acceptability of FDA filings and the efficacy and
marketability of potential products, involve risks and
uncertainties that could cause actual results to differ materially
from predicted results. These risks include: delays in obtaining or
inability to obtain FDA, institutional review board or other
regulatory approvals of preclinical or clinical testing;
unfavorable outcomes in our preclinical and clinical testing; the
development by others of competing technologies and therapeutics
that may have greater efficacy or lower cost; delays in obtaining
or inability to obtain FDA or other necessary regulatory approval
of our products; our inability to successfully and cost effectively
develop or outsource manufacturing and marketing of any products we
are able to bring to market; changes in FDA or other regulations
that affect our ability to obtain regulatory approval of our
products, increase our manufacturing costs or limit our ability to
market our products; our possible need for additional capital in
the future to fund the continued development of our Chrysalin
Product Platform; and other factors discussed in our Form 10-K for
the fiscal year ended December 31, 2004 our Form 10-Q for the
quarter ended September 30, 2005, and other documents we file with
the Securities and Exchange Commission. Editors' Note: This press
release is also available under the Investors section of the
Company's website at: http://www.orthologic.com/. DATASOURCE:
OrthoLogic Corp. CONTACT: media, Lauren Tortorete of Biosector 2,
+1-212-845-5609, , for OrthoLogic Corp.; or investors, Melanie
Friedman of Stern Investor Relations, +1-212-362-1200, for
OrthoLogic Corp. Web site: http://www.orthologic.com/
Copyright
Orthologic (MM) (NASDAQ:OLGC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Orthologic (MM) (NASDAQ:OLGC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Orthologic (MM) (NASDAQ): 0 recent articles
Más de Orthologic (MM) Artículos de Noticias